Skip to main content

Table 6 Rates of AOEs non-adjudicated and adjudicated AOEs in CP-CML patients (n = 270)

From: Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee

AOE Non-adjudicated eventsa Adjudicated eventsb
Any Serious Any Serious
Any, 84 (31) 69 (26) 57 (21) 54 (20)
 Cardiovascularc 42 (16) 33 (12) 26 (10) 25 (9)
 Cerebrovascular 35 (13) 28 (10) 25 (9) 22 (8)
 Peripheral vascular 38 (14) 31 (11) 31 (11) 26 (10)
Exposure-adjusted newly occurring AOEs, patients with events per 100 patient-years 11.3 9.3 8.7 8.1
  1. Data are no. (%) of patients, unless otherwise specified
  2. AOE arterial occlusive event, CP-CML chronic-phase chronic myeloid leukemia, MedDRA Medical Dictionary for Regulatory Activities, MI myocardial infarction, PT preferred term
  3. aCategorization of AOEs is based on > 400 MedDRA preferred terms related to vascular ischemia or thrombosis
  4. bEvents that were adjudicated as an AOE by the adjudication committee
  5. cDoes not include arterial hypertension AEs